Skip to main content
Top
Published in: American Journal of Cardiovascular Drugs 5/2007

01-09-2007 | Review Article

The Tragedy of TRIUMPH for Nitric Oxide Synthesis Inhibition in Cardiogenic Shock

Where Do We Go from Here?

Authors: Alison Bailey, Theodore W. Pope, Scott A. Moore, Dr Charles L. Campbell

Published in: American Journal of Cardiovascular Drugs | Issue 5/2007

Login to get access

Abstract

Cardiogenic shock following an acute coronary syndrome (ACS) continues to be associated with significant mortality despite modern reperfusion strategies and inotropic support. There is mounting evidence that an acute inflammatory response accompanies the well documented decrement in left ventricular systolic function associated with cardiogenic shock and that this response may affect outcomes. In the past 2 decades it has also become apparent that nitric oxide (NO), a heteroatomic free radical has numerous biologic activities, among them the maintenance of vascular tone. The production of NO is mediated by three nitric oxide synthases (NOS); the transcription of one of these (NOS2 or inducible NOS [iNOS]) is induced by inflammatory stimuli. The iNOS gene product produces NO at very high and potentially pathologic levels. The up-regulation of iNOS transcription and overproduction of NO have been implicated in the pathogenesis of shock states where excess NO is thought to cause catecholamine resistant vasodilatation and reduced myocardial inotropy, resulting in hypotension and a fall in cardiac output. NO can also react with superoxide to produce peroxynitrate, a molecule directly toxic to the cells via modification of proteins and DNA. Inhibitors of NOS have long been utilized in the laboratory characterization of the NOS. More recently, attempts have been made to determine if the inhibition of NOS might have clinical utility in the setting of circulatory shock. With respect to septic shock, early animal studies and small trials in humans proved encouraging, but a larger trial was terminated early because of a trend toward harm among patients receiving the NO inhibitor. Studies have been undertaken in the setting of cardiogenic shock. Animal studies and small trials with humans again proved encouraging, but the large randomized TRIUMPH trial evaluating tilarginine (N G -monomethyl-L-arginine; L-NMMA) was recently terminated because of a lack of efficacy. These studies evaluated compounds with little selectivity for iNOS and their failure may have been due, in part, to the inhibition of the other NOS isoforms. In this review, we describe the biochemistry of NO synthesis, the regulation of NO production, and the clinical trials evaluating the efficacy of NOS inhibition with an eye to future trials with more selective inhibitors of iNOS.
Literature
1.
go back to reference Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999 Apr 15; 340 (15): 1162–8.PubMedCrossRef Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999 Apr 15; 340 (15): 1162–8.PubMedCrossRef
2.
go back to reference Hasdai D, Topol EJ, Califf RM, et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000 Aug 26; 356 (9231): 749–56.PubMedCrossRef Hasdai D, Topol EJ, Califf RM, et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000 Aug 26; 356 (9231): 749–56.PubMedCrossRef
3.
go back to reference Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005 Jul 27; 294 (4): 448–54.PubMedCrossRef Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005 Jul 27; 294 (4): 448–54.PubMedCrossRef
4.
go back to reference Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006 May 23; 113 (20): 2398–405.PubMedCrossRef Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006 May 23; 113 (20): 2398–405.PubMedCrossRef
5.
go back to reference Holmes Jr DR, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995 Sep; 26 (3): 668–74.PubMedCrossRef Holmes Jr DR, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995 Sep; 26 (3): 668–74.PubMedCrossRef
6.
go back to reference Iakobishvili Z, Behar S, Boyko V, et al. Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? Am Heart J 2005 Jan; 149 (1): 98–103.PubMedCrossRef Iakobishvili Z, Behar S, Boyko V, et al. Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines? Am Heart J 2005 Jan; 149 (1): 98–103.PubMedCrossRef
7.
go back to reference Tipoo FA, Quraishi AR, Najaf SM, et al. Outcome of cardiogenic shock complicating acute myocardial infarction. J Coll Physicians Surg Pak 2004 Jan; 14 (1): 6–9.PubMed Tipoo FA, Quraishi AR, Najaf SM, et al. Outcome of cardiogenic shock complicating acute myocardial infarction. J Coll Physicians Surg Pak 2004 Jan; 14 (1): 6–9.PubMed
8.
go back to reference Lindholm MG, Kober L, Boesgaard S, et al. Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J 2003 Feb; 24 (3): 258–65.PubMedCrossRef Lindholm MG, Kober L, Boesgaard S, et al. Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J 2003 Feb; 24 (3): 258–65.PubMedCrossRef
9.
go back to reference Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988 Dec; 78 (6): 1345–51.PubMedCrossRef Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988 Dec; 78 (6): 1345–51.PubMedCrossRef
10.
go back to reference Hibbard MD, Holmes Jr DR, Bailey KR, et al. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992 Mar 1; 19 (3): 639–46.PubMedCrossRef Hibbard MD, Holmes Jr DR, Bailey KR, et al. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992 Mar 1; 19 (3): 639–46.PubMedCrossRef
11.
go back to reference Moosvi AR, Khaja F, Villanueva L, et al. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992 Apr; 19 (5): 907–14.PubMedCrossRef Moosvi AR, Khaja F, Villanueva L, et al. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992 Apr; 19 (5): 907–14.PubMedCrossRef
12.
go back to reference Gacioch GM, Ellis SG, Lee L, et al. Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol 1992 Mar 1; 19 (3): 647–53.PubMedCrossRef Gacioch GM, Ellis SG, Lee L, et al. Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol 1992 Mar 1; 19 (3): 647–53.PubMedCrossRef
13.
go back to reference Eltchaninoff H, Simpfendorfer C, Franco I, et al. Early and 1-year survival rates in acute myocardial infarction complicated by cardiogenic shock: a retrospective study comparing coronary angioplasty with medical treatment. Am Heart J 1995 Sep; 130 (3 Pt 1): 459–64.PubMedCrossRef Eltchaninoff H, Simpfendorfer C, Franco I, et al. Early and 1-year survival rates in acute myocardial infarction complicated by cardiogenic shock: a retrospective study comparing coronary angioplasty with medical treatment. Am Heart J 1995 Sep; 130 (3 Pt 1): 459–64.PubMedCrossRef
14.
go back to reference Berger PB, Holmes Jr DR, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial: an observational study. Circulation 1997 Jul 1; 96 (1): 122–7.PubMedCrossRef Berger PB, Holmes Jr DR, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial: an observational study. Circulation 1997 Jul 1; 96 (1): 122–7.PubMedCrossRef
15.
go back to reference Hochman JS, Sleeper LA, Webb JG, et al., for the SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. New Engl J Med 1999 Aug 26; 341 (9): 625–34.PubMedCrossRef Hochman JS, Sleeper LA, Webb JG, et al., for the SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. New Engl J Med 1999 Aug 26; 341 (9): 625–34.PubMedCrossRef
16.
go back to reference Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001 Jan 10; 285 (2): 190–2.PubMedCrossRef Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001 Jan 10; 285 (2): 190–2.PubMedCrossRef
17.
go back to reference Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003 Jun 24; 107 (24): 2998–3002.PubMedCrossRef Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003 Jun 24; 107 (24): 2998–3002.PubMedCrossRef
18.
go back to reference Sleeper LA, Ramanathan K, Picard MH, et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005 Jul 19; 46 (2): 266–73.PubMedCrossRef Sleeper LA, Ramanathan K, Picard MH, et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005 Jul 19; 46 (2): 266–73.PubMedCrossRef
19.
go back to reference Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000 Apr 1; 108 (5): 374–80.PubMedCrossRef Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000 Apr 1; 108 (5): 374–80.PubMedCrossRef
20.
go back to reference Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005 Oct; 26 (19): 1964–70.PubMedCrossRef Theroux P, Armstrong PW, Mahaffey KW, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005 Oct; 26 (19): 1964–70.PubMedCrossRef
21.
go back to reference Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995 Aug 15; 92 (4): 748–55.PubMedCrossRef Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995 Aug 15; 92 (4): 748–55.PubMedCrossRef
22.
go back to reference Ott I, Neumann FJ, Kenngott S, et al. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol 1998 Oct 15; 82 (8): 938–42.PubMedCrossRef Ott I, Neumann FJ, Kenngott S, et al. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction. Am J Cardiol 1998 Oct 15; 82 (8): 938–42.PubMedCrossRef
23.
go back to reference Geppert A, Steiner A, Zorn G, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002 Sep; 30 (9): 1987–94.PubMedCrossRef Geppert A, Steiner A, Zorn G, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002 Sep; 30 (9): 1987–94.PubMedCrossRef
24.
go back to reference Geppert A, Dorninger A, Delle-Karth G, et al. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006 Aug; 34 (8): 2035–42.PubMedCrossRef Geppert A, Dorninger A, Delle-Karth G, et al. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006 Aug; 34 (8): 2035–42.PubMedCrossRef
25.
go back to reference Pudil R, Krejsek J, Pidrman V, et al. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica (Firadec Kralove) 2001; 44(4): 149–51. Pudil R, Krejsek J, Pidrman V, et al. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica (Firadec Kralove) 2001; 44(4): 149–51.
26.
go back to reference Kohsaka S, Menon V, Lowe AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005 M 25; 165 (14): 1643–50.PubMedCrossRef Kohsaka S, Menon V, Lowe AM, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005 M 25; 165 (14): 1643–50.PubMedCrossRef
27.
go back to reference Pope TW, Moore SA, Campbell CL. Nitric oxide synthesis in cardiogenic shock: too much of a good thing. Acute Coron Syndromes 2006; 7 (4): 106–11. Pope TW, Moore SA, Campbell CL. Nitric oxide synthesis in cardiogenic shock: too much of a good thing. Acute Coron Syndromes 2006; 7 (4): 106–11.
28.
go back to reference Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987 Dec; 84 (24): 9265–9.PubMedCrossRef Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987 Dec; 84 (24): 9265–9.PubMedCrossRef
29.
go back to reference Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987 Jun 11–17; 327 (6122): 524–6.PubMedCrossRef Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987 Jun 11–17; 327 (6122): 524–6.PubMedCrossRef
30.
go back to reference Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 Nov 27; 288 (5789): 373–6.PubMedCrossRef Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 Nov 27; 288 (5789): 373–6.PubMedCrossRef
31.
go back to reference Lancaster Jr JR. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1997 Feb; 1 (1): 18–30.PubMedCrossRef Lancaster Jr JR. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1997 Feb; 1 (1): 18–30.PubMedCrossRef
32.
go back to reference Garcin ED, Bruns CM, Lloyd SJ, et al. Structural basis for isozyme-specific regulation of electron transfer in nitric-oxide synthase. J Biol Chem 2004 Sep 3; 279 (36): 37918–27.PubMedCrossRef Garcin ED, Bruns CM, Lloyd SJ, et al. Structural basis for isozyme-specific regulation of electron transfer in nitric-oxide synthase. J Biol Chem 2004 Sep 3; 279 (36): 37918–27.PubMedCrossRef
33.
go back to reference Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001 Aug 1; 357 (Pt 3): 593–615.PubMedCrossRef Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001 Aug 1; 357 (Pt 3): 593–615.PubMedCrossRef
34.
go back to reference Feron O, Michel T. Cell and molecular biology of nitric oxide synthases. Totowa (NJ): Humana Press, 2000. Feron O, Michel T. Cell and molecular biology of nitric oxide synthases. Totowa (NJ): Humana Press, 2000.
35.
go back to reference Bruckdorfer R. The basics about nitric oxide. Mol Aspects Med 2005 Feb–Apr; 26 (1–2): 3–31. Bruckdorfer R. The basics about nitric oxide. Mol Aspects Med 2005 Feb–Apr; 26 (1–2): 3–31.
36.
go back to reference Kiechle FL, Malinski T. Nitric oxide: biochemistry, pathophysiology, and detection. Am J Clin Pathol 1993 Nov; 100 (5): 567–75.PubMed Kiechle FL, Malinski T. Nitric oxide: biochemistry, pathophysiology, and detection. Am J Clin Pathol 1993 Nov; 100 (5): 567–75.PubMed
37.
go back to reference Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002 Mar 21; 416 (6878): 337–9.PubMedCrossRef Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002 Mar 21; 416 (6878): 337–9.PubMedCrossRef
38.
go back to reference Klein JA, Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 2003 Mar; 111 (6): 785–93.PubMed Klein JA, Ackerman SL. Oxidative stress, cell cycle, and neurodegeneration. J Clin Invest 2003 Mar; 111 (6): 785–93.PubMed
39.
go back to reference Firuzi O, Fuksa L, Spadaro C, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006 Jul; 58 (7): 951–7.PubMedCrossRef Firuzi O, Fuksa L, Spadaro C, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006 Jul; 58 (7): 951–7.PubMedCrossRef
40.
go back to reference Elfering SL, Sarkela TM, Giulivi C. Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem 2002 Oct 11; 277 (41): 38079–86.PubMedCrossRef Elfering SL, Sarkela TM, Giulivi C. Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem 2002 Oct 11; 277 (41): 38079–86.PubMedCrossRef
41.
go back to reference Giulivi C, Poderoso JJ, Boveris A. Production of nitric oxide by mitochondria. J Biol Chem 1998 May 1; 273 (18): 11038–43.PubMedCrossRef Giulivi C, Poderoso JJ, Boveris A. Production of nitric oxide by mitochondria. J Biol Chem 1998 May 1; 273 (18): 11038–43.PubMedCrossRef
42.
go back to reference Tatoyan A, Giulivi C. Purification and characterization of a nitric-oxide synthase from rat liver mitochondria. J Biol Chem 1998 May 1; 273 (18): 11044–8.PubMedCrossRef Tatoyan A, Giulivi C. Purification and characterization of a nitric-oxide synthase from rat liver mitochondria. J Biol Chem 1998 May 1; 273 (18): 11044–8.PubMedCrossRef
43.
go back to reference Chen X, Niroomand F, Liu Z, et al. Expression of nitric oxide related enzymes in coronary heart disease. Basic Res Cardiol 2006 Jul; 101 (4): 346–53.PubMedCrossRef Chen X, Niroomand F, Liu Z, et al. Expression of nitric oxide related enzymes in coronary heart disease. Basic Res Cardiol 2006 Jul; 101 (4): 346–53.PubMedCrossRef
44.
go back to reference Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide synthase: time for reappraisal. Curr Drug Targets Inflamm Allergy 2002 Mar; 1(1): 89–108.PubMedCrossRef Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide synthase: time for reappraisal. Curr Drug Targets Inflamm Allergy 2002 Mar; 1(1): 89–108.PubMedCrossRef
45.
go back to reference Schilling K, Opitz N, Wiesenthal A, et al. Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveolin-1 and NOSTRIN. Mol Biol Cell 2006 Sep; 17 (9): 3870–80.PubMedCrossRef Schilling K, Opitz N, Wiesenthal A, et al. Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveolin-1 and NOSTRIN. Mol Biol Cell 2006 Sep; 17 (9): 3870–80.PubMedCrossRef
46.
go back to reference Li XA, Everson WV, Smart EJ. Caveolae, lipid rafts, and vascular disease. Trends Cardiovasc Med 2005 Apr; 15 (3): 92–6.PubMedCrossRef Li XA, Everson WV, Smart EJ. Caveolae, lipid rafts, and vascular disease. Trends Cardiovasc Med 2005 Apr; 15 (3): 92–6.PubMedCrossRef
47.
go back to reference Glynne PA, Darling KE, Picot J, et al. Epithelial inducible nitric-oxide synthase is an apical EBP50-binding protein that directs vectorial nitric oxide output. J Biol Chem 2002 Sep 6; 277 (36): 33132–8.PubMedCrossRef Glynne PA, Darling KE, Picot J, et al. Epithelial inducible nitric-oxide synthase is an apical EBP50-binding protein that directs vectorial nitric oxide output. J Biol Chem 2002 Sep 6; 277 (36): 33132–8.PubMedCrossRef
48.
go back to reference Oess S, Icking A, Fulton D, et al. Subcellular targeting and trafficking of nitric oxide synthases. Biochem J 2006 Jun 15; 396 (3): 401–9.PubMedCrossRef Oess S, Icking A, Fulton D, et al. Subcellular targeting and trafficking of nitric oxide synthases. Biochem J 2006 Jun 15; 396 (3): 401–9.PubMedCrossRef
49.
go back to reference Michel JB, Feron O, Sase K, et al. Caveolin versus calmodulin: counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 1997 Oct 10; 272 (41): 25907–12.PubMedCrossRef Michel JB, Feron O, Sase K, et al. Caveolin versus calmodulin: counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 1997 Oct 10; 272 (41): 25907–12.PubMedCrossRef
50.
go back to reference Pannu R, Singh I. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int 2006 Jul; 49 (2): 170–82.PubMedCrossRef Pannu R, Singh I. Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int 2006 Jul; 49 (2): 170–82.PubMedCrossRef
51.
go back to reference Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 2004 Mar 15; 36 (6): 707–17.PubMedCrossRef Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med 2004 Mar 15; 36 (6): 707–17.PubMedCrossRef
52.
go back to reference Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006 Apr; 26 (4): 697–705.PubMedCrossRef Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006 Apr; 26 (4): 697–705.PubMedCrossRef
53.
go back to reference Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005 Feb–Apr; 26 (1–2): 33–65.PubMedCrossRef Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005 Feb–Apr; 26 (1–2): 33–65.PubMedCrossRef
54.
go back to reference Brown GC, Borutaite V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 2004 Jul 23; 1658 (1–2): 44–9.PubMed Brown GC, Borutaite V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim Biophys Acta 2004 Jul 23; 1658 (1–2): 44–9.PubMed
55.
go back to reference Hess DT, Matsumoto A, Kim SO, et al. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005 Feb; 6 (2): 150–66.PubMedCrossRef Hess DT, Matsumoto A, Kim SO, et al. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005 Feb; 6 (2): 150–66.PubMedCrossRef
56.
go back to reference Nakae H, Endo S, Kikuchi M, et al. Nitrite/nitrate (NOx) levels and hemodynamics during septic shock. Surg Today 2000; 30 (8): 683–8.PubMedCrossRef Nakae H, Endo S, Kikuchi M, et al. Nitrite/nitrate (NOx) levels and hemodynamics during septic shock. Surg Today 2000; 30 (8): 683–8.PubMedCrossRef
57.
go back to reference Endo S, Inada K, Nakae H, et al. Nitrite/nitrate oxide (NOx) and cytokine levels in patients with septic shock: research communications in molecular pathology and pharmacology. Res Commun Mol Pathol Pharmacol 1996 Mar; 91 (3): 347–56.PubMed Endo S, Inada K, Nakae H, et al. Nitrite/nitrate oxide (NOx) and cytokine levels in patients with septic shock: research communications in molecular pathology and pharmacology. Res Commun Mol Pathol Pharmacol 1996 Mar; 91 (3): 347–56.PubMed
58.
go back to reference Ruetten H, Thiemermann C. Shock states and nitric oxide. Totowa (NJ): Humana Press, 2000. Ruetten H, Thiemermann C. Shock states and nitric oxide. Totowa (NJ): Humana Press, 2000.
59.
go back to reference Evans T, Carpenter A, Kinderman H, et al. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993 Oct; 41 (2): 77–81.PubMed Evans T, Carpenter A, Kinderman H, et al. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993 Oct; 41 (2): 77–81.PubMed
60.
go back to reference Kilbourn RG, Cromeens DM, Chelly FD, et al. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Crit Care Med 1994 Nov; 22 (11): 1835–40.PubMed Kilbourn RG, Cromeens DM, Chelly FD, et al. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Crit Care Med 1994 Nov; 22 (11): 1835–40.PubMed
61.
go back to reference Lorente JA, Landin L, De Pablo R, et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993 Sep; 21 (9): 1287–95.PubMedCrossRef Lorente JA, Landin L, De Pablo R, et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993 Sep; 21 (9): 1287–95.PubMedCrossRef
62.
go back to reference Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994 Jan; 28 (1): 34–9.PubMedCrossRef Petros A, Lamb G, Leone A, et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994 Jan; 28 (1): 34–9.PubMedCrossRef
63.
go back to reference Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, et al. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med 1998 Apr; 26 (4): 660–7.PubMedCrossRef Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, et al. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med 1998 Apr; 26 (4): 660–7.PubMedCrossRef
64.
go back to reference Avontuur JA, Tutein Nolthenius RP, Buijk SL, et al. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock. Chest 1998 Jun; 113 (6): 1640–6.PubMedCrossRef Avontuur JA, Tutein Nolthenius RP, Buijk SL, et al. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock. Chest 1998 Jun; 113 (6): 1640–6.PubMedCrossRef
65.
go back to reference Grover R, Zaccardelli D, Colice G, et al. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 1999 May; 27 (5): 913–22.PubMedCrossRef Grover R, Zaccardelli D, Colice G, et al. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 1999 May; 27 (5): 913–22.PubMedCrossRef
66.
go back to reference Bakker J, Grover R, McLuckie A, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). Crit Care Med 2004 Jan; 32 (1): 1–12.PubMedCrossRef Bakker J, Grover R, McLuckie A, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144–002). Crit Care Med 2004 Jan; 32 (1): 1–12.PubMedCrossRef
67.
go back to reference Keaney Jr JF, Hare JM, Balligand JL, et al. Inhibition of nitric oxide synthase augments myocardial contractile responses to beta-adrenergic stimulation. Am J Physiol 1996 Dec; 271 (6 Pt 2): H2646–52.PubMed Keaney Jr JF, Hare JM, Balligand JL, et al. Inhibition of nitric oxide synthase augments myocardial contractile responses to beta-adrenergic stimulation. Am J Physiol 1996 Dec; 271 (6 Pt 2): H2646–52.PubMed
68.
go back to reference Hare JM, Keaney Jr JF, Balligand JL, et al. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest 1995 Jan; 95 (1): 360–6.PubMedCrossRef Hare JM, Keaney Jr JF, Balligand JL, et al. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest 1995 Jan; 95 (1): 360–6.PubMedCrossRef
69.
go back to reference Salerno L, Sorrenti V, Di Giacomo C, et al. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 2002; 8 (3): 177–200.PubMedCrossRef Salerno L, Sorrenti V, Di Giacomo C, et al. Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 2002; 8 (3): 177–200.PubMedCrossRef
70.
go back to reference Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000 Mar 28; 101 (12): 1358–61.PubMedCrossRef Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000 Mar 28; 101 (12): 1358–61.PubMedCrossRef
71.
go back to reference Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003 Jul; 24 (14): 1287–95.PubMedCrossRef Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003 Jul; 24 (14): 1287–95.PubMedCrossRef
72.
go back to reference Dzavik V, Cotter G, Reynolds HR, al. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with persisitent cardiogenic shock complicating acute myocardial infarction: a phase II dose ranging study. Eur Heart J 2007 May; 28 (9): 1109–16.PubMedCrossRef Dzavik V, Cotter G, Reynolds HR, al. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with persisitent cardiogenic shock complicating acute myocardial infarction: a phase II dose ranging study. Eur Heart J 2007 May; 28 (9): 1109–16.PubMedCrossRef
73.
go back to reference Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007 Apr 18; 297 (15): 1657–66.PubMedCrossRef Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007 Apr 18; 297 (15): 1657–66.PubMedCrossRef
74.
go back to reference Moncada S, Erusalimsky JD. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 2002 Mar; 3 (3): 214–20.PubMedCrossRef Moncada S, Erusalimsky JD. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 2002 Mar; 3 (3): 214–20.PubMedCrossRef
75.
go back to reference Low SY. Application of Pharmaceuticals to nitric oxide. Mol Aspects Med 2005 Feb–Apr; 26 (1–2): 97–138.PubMedCrossRef Low SY. Application of Pharmaceuticals to nitric oxide. Mol Aspects Med 2005 Feb–Apr; 26 (1–2): 97–138.PubMedCrossRef
Metadata
Title
The Tragedy of TRIUMPH for Nitric Oxide Synthesis Inhibition in Cardiogenic Shock
Where Do We Go from Here?
Authors
Alison Bailey
Theodore W. Pope
Scott A. Moore
Dr Charles L. Campbell
Publication date
01-09-2007
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 5/2007
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/00129784-200707050-00003

Other articles of this Issue 5/2007

American Journal of Cardiovascular Drugs 5/2007 Go to the issue